Collectively, our study proposed a novel regulatory pathway of YTHDF1, which provided a new idea for breast cancer treatment and suggested that YTHDF1 may be a potential biomarker and therapeutic target for breast cancer patients. Here, YTHDF1 is linked to breast carcinoma.